All In Biotech

Drug Trial Radar · NCT06448676

Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides

Head-to-Head Comparison of the Efficacy and Safety of All Five Commercially Available Botulinum Neurotoxin Type A Products for the Treatment of Glabellar Rhytides: A Multicenter, Double-Blind, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

325

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Jan 15, 2027

Study completion Feb 1, 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Universitair Medical Centrum Groningen
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study Type: This is a multicenter, triple-blind, randomized controlled trial. Purpose: The goal of this clinical trial is to compare the effectiveness and safety of all commercially available Botulinum Neurotoxin Type A (BoNT-A) products for treating glabellar rhytides, commonly known as frown lines. This study is designed to provide comprehensive data on how these treatments compare in terms of improving frown lines and the duration of their effects. Main Questions the Study Aims to Answer: Which BoNT-A product provides the longest lasting effect on reducing glabellar rhytides? How do these products compare in terms of safety and the occurrence of side effects? Participant Tasks: Women aged 18 years or older with moderate to severe glabellar lines will participate. Participants will receive injections of a BoNT-A product into specific facial muscles. They will need to take weekly photographs using their smartphones to document changes in their frown lines. These photos will be securely sent to our research team for analysis. Participants will complete questionnaires at the start and end of the study to assess their satisfaction, quality of life, and any changes in their condition. Comparison Group: Researchers will compare participants receiving different types of BoNT-A products to see which one is more effective at reducing frown lines and maintaining these effects over time. The safety profiles of these products will also be compared to determine which has the fewest and least severe side effects. This study aims to fill important gaps in our understanding of Botulinum Neurotoxin Type A treatments, guiding more effective clinical decisions and improving patient outcomes.

Conditions

  • Wrinkle
  • Glabellar Frown Lines
  • Glabellar Furrowing

Interventions

  • Botulinum toxin type ADrug

    Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Clinical EfficacyTime frame: From baseline to week 16

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Faceland

    Amsterdam, Netherlands · Recruiting

  • Faceland

    Eindhoven, Netherlands · Recruiting

  • Faceland

    Utrecht, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.